Breaking News
protalix biotherapeutics unveils q1 results corporate insights 2508

Stock Market

Protalix BioTherapeutics Unveils Q1 Results & Corporate Insights


Michael Chen

May 3, 2024 - 10:50 am


Protalix BioTherapeutics to Announce First Quarter Financial Results and Host Corporate Update Call

CARMIEL, Israel, May 3, 2024 /PRNewswire/—Protalix BioTherapeutics, Inc. (NYSE American: PLX), a pioneering biopharmaceutical company specializing in the development, manufacturing, and commercialization of recombinant therapeutic proteins, has announced that it will publicly release its financial outcomes for the first quarter ending March 31, 2024. The release is scheduled for May 10, 2024, along with a comprehensive update on business operations and clinical advances.

The management team plans to host a conference call to engage with investors, discussing the quarter's financial results and illuminating the recent strides in corporate and regulatory realms.

Conference Call and Webcast Arrangements Detailed

Date and Time: The conference has been slated for Friday, May 10, 2024, precisely at 8:30 a.m. Eastern Daylight Time (EDT). This timing promises to accommodate a broad audience across various time zones and extend the reach of this highly anticipated discussion.

Access Details:

  • Toll-Free Number: 1-877-423-9813 allows seamless connectivity without charges for participants dialing in from the United States.
  • International Access: For global stakeholders, the number is clearly marked as 1-201-689-8573.
  • Israeli Toll Free: The dedicated number for Israeli participants is 1 809 406 247.
  • Conference ID: The pivotal access code for this conference is 13745800.

Furthermore, Protalix provides a revolutionary in-call feature called Call me™—a tech-savvy option enabling you to bypass the wait time for a conference operator. Interested parties can simply visit, enter their phone number, and the system will initiate the call immediately.

Points to Note for Webcast Participants

Webcast Connection:

  • Company Webcast Page: The event can be tracked live online via the company's events page accessible at This feature allows for a broader audience reach, including those unable to join via the teleconference.
  • Direct Webcast Link: A secondary access point directly to the webcast is established through, where the same Conference ID: 13745800 is applicable.

The company advises participants to connect at least fifteen minutes before the conference begins to register and if needed, to set up any essential software for the audio stream. Moreover, a replay of the entire call will subsequently be available on the company's website under the Investors section's Events Calendar, reaffirming Protalix’s commitment to transparency and stakeholder engagement.

Pioneering Advances Under Protalix BioTherapeutics, Inc.

Protalix has solidly positioned itself as an innovator in biopharmaceuticals, fundamentally renewing the way recombinant therapeutic proteins are developed through its proprietary ProCellEx® plant cell-based expression system. This groundbreaking technology has not only yielded significant scientific advancements but also achieved the historical milestone of being the first to receive approval from the U.S. Food and Drug Administration (FDA) for a protein produced via plant cell-based in suspension system—a significant testament to the company’s innovative capabilities.

The first triumph of Protalix was the licensing of taliglucerase alfa, a game-changing treatment for Gaucher disease, to Pfizer Inc. for global development and commercialization rights, while expertly retaining full rights within the Brazilian market. The company's second groundbreaking product, Elfabrio®, has already been approved by both the FDA and the European Medicines Agency as of May 2023.

An Expanding Global Footprint and Dynamic Pipeline

As a testament to Protalix's growing international significance, a strategic alliance was formed with Chiesi Farmaceutici S.p.A. for the worldwide development and commercialization of Elfabrio. This strategic partnership underscores the global potential and medical breakthrough that Elfabrio represents.

Deepening its commitment to innovation, Protalix continues to expand its development pipeline, focusing on proprietary versions of recombinant therapeutic proteins that tap into well-established pharmaceutical markets. Among these promising product candidates are:

  • PRX–115, a plant cell-expressed PEGylated uricase aimed at treating patients with uncontrolled gout, a condition desperately in need of novel treatment options.
  • PRX–119, another plant cell-expressed long-acting DNase I, uniquely formulated to address NETs-related diseases, demonstrating Protalix's dedication to tackling a broad spectrum of medical challenges.

The company maintains a robust pipeline with an assortment of other advanced-stage product candidates, each tailored to address the unmet needs in different therapeutic areas.

Protalix BioTherapeutics Commits to Investor Relations and Transparency

Protalix understands the importance of maintaining open channels of communication with its investors, which is expertly managed by Mike Moyer serving as the Managing Director of LifeSci Advisors. Holding an impressive track record and extensive insight into the industry, Mr. Moyer is reachable via his contact at +1-617-308-4306, or through email at [email protected]. His role ensures that investment relations are not only sustained but nurtured through direct engagement and clear information dissemination.

The copious efforts made to keep stakeholders informed underscores a corporate ethos deeply rooted in transparency and accountability—a principle that holds paramount importance in the realms of biotechnology and pharmaceuticals, where investor confidence and public trust are crucial.

Corporate Emblem and Visual Identity

Protalix BioTherapeutics extends its brand visibility through visual elements such as its corporate logo, which can be viewed at This logo represents more than just the company’s visual identity; it is a symbol of the innovative spirit and relentless pursuit of medical advancements that define Protalix.


Protalix BioTherapeutics continues to forge a path forward in the realm of biopharmaceuticals with its innovative approach to protein expression and commitment to addressing critical medical needs. The upcoming financial results and corporate update are highly anticipated events that will provide investors and industry watchers with deep insights into the company's performance and strategic direction.

In this digital age, the company’s inclusive approach in hosting webcasts and providing easy access to the conference call details reflects an understanding of the need to engage a global audience. The comprehensive discussion slated for May 10, 2024, will serve as a testament to Protalix's continued dedication to its stakeholders and patients worldwide, driven by its ground-breaking ProCellEx® technology and an expanding product pipeline aimed at revolutionizing therapeutic standards and improving lives.

As Protalix BioTherapeutics, Inc. gears up to present its first-quarter financials and offers a peek into the company's future undertakings, the biopharmaceutical industry looks on with keen interest. The progressive strides achieved by Protalix are not merely metrics of financial growth but harbingers of better health outcomes for patients globally. With investor relations held in high regard and an unyielding dedication to advancing human health, Protalix remains a beacon of hope and a source of inspiration within the scientific and medical communities.

Moving forward, Protalix's story is far from complete. The company's innovative therapies and treatments have already begun to leave an indelible mark on the world, with many more promising ventures on the horizon. As stakeholders prepare to tune into the upcoming conference, the air is thick with anticipation for what Protalix will unveil next.

The future holds limitless potential for Protalix BioTherapeutics, as its products, like Elfabrio® and the promising PRX–115 and PRX–119, continue to advance through the regulatory pathways and reach patients in need. The growth in partnerships, successful launches, and novel treatments are set to sculpt a new era of healthcare—one where innovative plant cell-based protein expression systems redefine the boundaries of therapeutic possibilities.

May 10th marks not just another corporate update, but a milestone for Protalix BioTherapeutics, as it reaffirms its commitment to enhancing patient health through biopharmaceutical innovation. As we witness the unfolding of this journey, one thing remains certain: Protalix is charting a course for a healthier tomorrow, one breakthrough at a time.